Understanding Key Issues in the Treatment of Castrate-Resistant Prostate Cancer
Source: Expert Guidance in Defining and Treating Castrate-Resistant Prostate Cancer

Module

David I. Quinn, MD, PhD, explores current approaches for managing patients with castrate-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Define the criteria by which a patient is classified as castrate resistant
  • Describe current treatment approaches for patients with castrate-resistant prostate cancer
  • Explain factors to consider when choosing treatment options for castrate-resistant prostate cancer patients
  • Cite novel research advances and therapeutic treatment options for the treatment of patients with castrate-resistant prostate cancer

Topics covered include:

  • Introduction
  • Definition of CRPC, Androgen-Independent Prostate Cancer, and Hormone-Refractory Prostate Cancer
  • Influence of Metastatic Site on Treatment Course
  • Optimal Androgen-Deprivation Therapy
  • Value of Secondary Hormone Therapy: Who Are the Ideal Candidates?
  • Current Treatment Approaches for CRPC
  • Therapeutic Alternatives Following Docetaxel Failure
  • Factors Influencing Choice of Treatment
  • Nomograms for the Treatment of CRPC
  • Future Strategies and Clinical Trial Data for CRPC
  • Future Treatment Approaches for CRPC: Bone Targeting Strategies
  • Immunotherapy for CRPC
 

Program Directors

  • David I. Quinn
    MD, PhD
    Nicholas J. Vogelzang
    MD

Faculty

  • David I. Quinn
    MD, PhD

Credit Information

  • Release Date:
    February 20, 2009
  • Expiration Date:
    February 19, 2010
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits